In addition, recent clinical data from large real-world datasets together with genome-wide association studies indicate that JAK/STAT signaling is altered in Alzheimer’s disease and is likely to be associated with inflammatory processes in Alzheimer’s disease and has, therefore, been proposed as a target for developing treatments for Alzheimer’s disease [17]. This evidence concerns the gene SOAT1 and early-onset autosomal dominant Alzheimer disease.